Systemic treatment with recombinant human epidermal growth factor accelerates healing of sclerotherapy-induced esophageal ulcers and prevents esophageal stricture formations in pigs
- 18 Downloads
Human epidermal growth factor (EGF), a small polypeptide (6 kDa) with mitogenic properties, has been implicated in the protection of gastrointestinal mucosal integrity. The efficacy of EGF in the prevention and healing of sclerotherapy-induced esophageal lesions was investigated in 24 minipigs with surgically induced portal hypertension. In addition, the effect of EGF on intragastric acidity and pharmacokinetics was investigated as possible means to explain its protective mechanism of action. The animals underwent three weekly sessions of sclerotherapy with polidocanol 2% and were concomitantly and for an additional three weeks treated with either placebo or EGF administered paravenously in the esophagus and/or subcutaneously. The subcutaneous treatment with EGF significantly (P<0.05) reduced esophageal stricture and scar formations associated with sclerotherapy. Gastric pH values were significantly (P<0.01) elevated only in animals receiving subcutaneous injections of EGF. Furthermore, the subcutaneous administration of EGF was associated with unexpected prolonged plasma concentration of the peptide. These results suggest a possible clinical value of EGF as an adjunctive treatment with the sclerotherapy.
Key wordsepidermal growth factor sclerotherapy esophageal ulcers
Unable to display preview. Download preview PDF.
- 3.Pulanic R, Vrhovac B, Jokic N, Rosandic-Pilas M, Salamon V, Opacic M, Rustemovic N, Korac C, Vucelic B: Prophylactic administration of ranitidine after sclerotherapy of esophageal varices. Int J Clin Pharmacol Toxicol 29:347–351, 1991Google Scholar
- 5.Paquet KJ, Koussouris P, Keinath R, Rambach W, Kalk J-F: A comparison of sucralfate with placebo in the treatment of esophageal ulcers following therapeutic endoscopic sclerotherapy of esophageal varices—a prospective controlled randomized trial. Am J Med 91:S147-S150, 1991Google Scholar
- 8.Bhargava DK, Garg P: Sclerotherapy associated esophageal ulcers: Omeprazole versus placebo—a double-blind randomized study. Abstract from Second Osaka International Symposium on Gastroenterology, Osaka, Japan. November 1993Google Scholar
- 17.Jensen LS, Krarup N, Larsen JA, Juhl C, Nielsen TH: Effect of acute portal hypertension on hepatosplanchnic hemodynamics and liver function. Scand J Gastroenterol 22:463–470, 1986Google Scholar
- 18.Weibel ER: Stereological Methods. Practical Methods for Biological Morphometry. New York, Academic Press, 1980Google Scholar
- 21.Sarin SK, Nanda R, Anand BS: Oesophageal ulceration after sclerotherapy—a complication or an accompaniment? Endoscopy 18:44–45, 1986Google Scholar
- 26.Olsen PS, Poulsen SS, Kirkegaard P, Nexø E: Role of submandibular saliva and epidermal growth factor in gastric cytoprotection. Gastroenterology 87:103–108, 1984Google Scholar